Outcome of Chronic Myeloid Leukemia-Chronic Phase Patients Treated With Imatinib: A Local Experience

Background

Imatinib was the first tyrosine kinase inhibitor that has revolutionized the therapy of chronic myeloid leukemia. It binds breakpoint cluster region–Abelson kinase domain inducing apoptosis of the leukemic cells. In this study, we assessed the efficacy and toxicity of imatinib therapy in patients with chronic myeloid leukemia in chronic phase (CML-CP) in our hospital.

284例胃间质瘤临床特征及预后分析

目的总结胃间质瘤临床特征及治疗方式,分析影响预后的因素。方法回顾分析2010年8月至2015年12月收治的284例行胃间质瘤手术患者的临床资料,采用电话回访及门诊复查进行随访,随访时间截至2016年9月30日。统计分析使用SPSS17.0软件进行,绘制生存曲线采用Kaplan-Meier法,单因素分析临床病理特征与胃间质瘤患者预后关系采用Log-rank检验,P0.05为差异具有统计学意义。结果 284例患者,其中男性132例,女性152例;年龄27~84岁,中位年龄60岁,胃间质瘤直径0.2~20 cm,中位直径4 cm,268例患者行免疫组织化学检测,其中CD117阳性的98.51%(264/268),CD34阳性的97.76%(262/268);改良NIH危险度分级:极低危41例,低危114例,中危58例,高危62例。177例获得随访(随访率62.32%),中位随访时间31.7个月(9.5~71.3个月)。单因素分析结果显示:手术根治性切除、肿瘤直径、改良NIH危险度分级与患者术后预后有关(P0.05)。结论胃间质瘤是常见的腹腔间质瘤,外科治疗是主要措施,手术根治性切除、肿瘤直径和NIH危险度分级是影响胃间质瘤预后的主要因素,药物靶向治疗一定程度改善患者预后。     

慢性髓性白血病衍生9号染色体ASS基因缺失与非缺失患者的临床特征

Objective To investigate the clinical characteristics of patients with chronic myeloid leukemia (CML) in chronic phase with deletion and non-deletion of the argininosuccinate synthesis gene (ASS gene) on the derivative chromosome 9. Methods The clinical data of patients with CML initially treated with imatinib and BCR/ABL1/ASS1 3-color fusion probe to detect ASS gene deletion were analyzed. The patients were divided into deletion group (n=27) and non-deletion group (n=92). Clinical characteristics, treatment effects, and prognosis were analyzed. Results The average age of 119 patients was 37.22±12.72 years old. The sokal score differed between the deletion and non-deletion groups (χ2=4.304, P=0.038). No statistically significant difference in other general characteristics was found (P>0.05). The 3-month CCyR rate, 6-month CCyR rate, and BCR-ABLIS≤1% rate in the deletion group were lower than those in the non-deletion group (P<0.05). The median follow-up of 119 patients was 35.0 (3.0-60.0) months. The PFS in the deletion group was lower than that in the non-deletion group (χ2=4.293, P=0.038). Overall survival was not significantly different between the two groups (χ2=0.008, P=0.931). Conclusion The deletion of the ASS gene in patients with chronic CML is related to the poor efficacy of imatinib treatment, poor prognosis, and high risk of disease progression. © 2023, CHINA RESEARCH ON PREVENTION AND TREATMENT. All rights reserved.     

Small,spontaneously ruptured gastrointestinal stromal tumor in the small intestine causing hemoperitoneum: A case report

IntroductionGastrointestinal stromal tumors (GISTs) are clinically asymptomatic until they reach a significant size; therefore, GISTs that are 2 cm or less are typically asymptomatic. Patients with symptomatic GISTs typically present with abdominal pain, gastrointestinal bleeding, or a palpable mass but rarely present with hemoperitoneum.Presentation of caseA 72-year-old Japanese man presented to us with acute onset abdominal pain. Physical examination showed peritoneal irritation in the lower abdomen. Findings of abdominal computed tomography were suggestive of hemoperitoneum; therefore, urgent surgery was performed. Approximately 1500 ml of blood in the abdominal cavity was removed. A small, ruptured mass was found in the middle of the small intestine, and partial resection of the small intestine, including the mass, was performed. The resected tumor was 2 cm in size and exhibited an exophytic growth pattern. Immunohistochemical staining revealed that the tumor was positive for KIT and CD34; therefore, a final diagnosis of GIST was made. Treatment with imatinib at 400 mg per day was started from postoperative month 1. The patient is doing well without recurrence 5 months after surgery.DiscussionEven small GISTs in the small intestine can spontaneously rupture and cause hemoperitoneum. Moreover, when a patient presents with sudden abdominal pain and hemoperitoneum without an evident mass on imaging, clinicians should be aware of the possibility of bleeding from a small GIST in the small intestine.ConclusionWe present an extremely rare case of a patient with a small, spontaneously ruptured GIST in the small intestine, resulting in hemoperitoneum.     

国产甲磺酸伊马替尼片在不同介质中的溶出曲线相似性评价

目的：考察2种国产甲磺酸伊马替尼片在多种溶出介质中溶出曲线的相似性,为临床用药提供参考。方法：采用桨法,转速50 r?min-1,分别以pH 1.2盐酸溶液、pH4.0醋酸-醋酸钠缓冲液、pH 6.8磷酸盐缓冲液和水作为溶出介质,溶出介质体积为1000 mL,采用紫外-可见分光光度法,检测波长为264 nm,分别测定2种国产甲磺酸伊马替尼片在不同时间点的平均累积溶出度,并绘制溶出曲线,评价二者溶出曲线的相似性。结果：在4种溶出介质中,2种国产甲磺酸伊马替尼片在15 min内溶出量均超过85%,说明二者溶出曲线具有相似性。结论：国产甲磺酸伊马替尼片的体外溶出行为具有相似性,故其质量一致性较好。     

晚期肠源性间质瘤临床特征和伊马替尼疗效分析

目的 探讨肠源性间质瘤的临床特征及伊马替尼治疗的疗效和预后因素。 方法 回顾性分析2004年1月至2016年1月于安徽医科大学第二附属医院门诊随访记录并筛选的肠源间质瘤共85例,根据原发部位将全组病例分为十二指肠组12例,小肠组64例,结直肠组9例。均行起始剂量400mg/d的甲磺酸伊马替尼口服治疗。客观疗效用Logistic回归分析,生存分析用Kaplan-Meier法,预后多因素分析用Cox回归模型。 结果 患者的性别、年龄和ECOG评分等因素对三组基线水平的影响未见明显差异。全组中共75例可评价疗效,其中CR 10例（13.3%）、PR 44例（58.7%）、SD 16例（21.3%）、PD 5例（6.7%）,RR为72.0%,DCR 为90.3%。三组RR和DCR的差异无统计学意义,但十二指肠组RR和DCR略低于小肠组和结直肠组。Logistic回归分析显示患者性别差异能够影响伊马替尼的疗效,女性患者应用伊马替尼能够取得更好的临床效果。全组患者的中位PFS为51.5个月,中位OS为63.5个月。1、2、3、5年生存率分别为96.4%、84.7%、79.2%和56.1%。十二指肠组、小肠组和结直肠组的中位PFS分别为23.0、51.5和58.5个月,中位OS分别为61.0、63.5和62.5个月。十二指肠组的PFS显著低于其余两组（P=0.034）,但三组的OS未见统计学差异（P=0.643）。肿瘤来源于十二指肠、肝转移、年龄＜65岁和获RR是影响PFS的独立因素;单纯肝转移是影响OS的独立因素。三组患者接受伊马替尼治疗后出现的主要不良反应主要为水肿、白细胞减少、腹泻、皮肤反应等。不良反应多为1～2级,3～4级少见,患者耐受性良好。各组不良反应仅呕吐和肾功能存在差异,其他差异均无统计学意义。 结论 晚期肠源GIST男性较多,接受伊马替尼治疗可显著改善患者的OS和PFS,十二指肠来源GIST的PFS明显低于小肠和结直肠来源GIST,肿瘤的原发部位、年龄和是否肝转移是影响患者生存的主要因素。